StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) stock

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.15−0.03 (-2.54%)

Close on Nov 17, 2026Market cap $121.17MP/E –Yield –

ProQR Therapeutics cash

Cash and short-term investments held at the end of each period.

ProQR Therapeutics's cash was €117.13M at Jun 30, 2026. For fiscal 2025 it was €92.41M, down 38.1% from the year before. Over ten years it grew -0.3% a year on average. The highest annual figure on record is €187.52M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025€92.41M-38.1%
FY2024Dec 31, 2024€149.41M+25.6%
FY2023Dec 31, 2023€118.93M+25.5%
FY2022Dec 31, 2022€94.78M-49.5%
FY2021Dec 31, 2021€187.52M+147.3%
FY2020Dec 31, 2020€75.84M-32.3%
FY2019Dec 31, 2019€111.95M+6.0%
FY2018Dec 31, 2018€105.58M+119.5%
FY2017Dec 31, 2017€48.10M-18.8%
FY2016Dec 31, 2016€59.20M-37.6%
FY2015Dec 31, 2015€94.87M-15.9%
FY2014Dec 31, 2014€112.74M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€117.13M-2.2%
Q1 FY2026Mar 31, 2026€81.09M-38.8%
Q4 FY2025Dec 31, 2025€92.41M-38.1%
Q3 FY2025Sep 30, 2025€106.88M+19.6%
Q2 FY2025Jun 30, 2025€119.77M+51.7%
Q1 FY2025Mar 31, 2025€132.41M+54.5%
Q4 FY2024Dec 31, 2024€149.41M+25.6%
Q3 FY2024Sep 30, 2024€89.40M-25.8%
Q2 FY2024Jun 30, 2024€78.97M-38.6%
Q1 FY2024Mar 31, 2024€85.71M-38.3%
Q4 FY2023Dec 31, 2023€118.93M+25.5%
Q3 FY2023Sep 30, 2023€120.55M+20.0%
Q2 FY2023Jun 30, 2023€128.56M-17.8%
Q1 FY2023Mar 31, 2023€138.99M-17.1%
Q4 FY2022Dec 31, 2022€94.78M-49.5%
Q3 FY2022Sep 30, 2022€100.43M-35.7%
Q2 FY2022Jun 30, 2022€156.40M+12.2%
Q1 FY2022Mar 31, 2022€167.61M+146.9%
Q4 FY2021Dec 31, 2021€187.52M+147.3%
Q3 FY2021Sep 30, 2021€156.14M+75.7%
Q2 FY2021Jun 30, 2021€139.44M+60.0%
Q1 FY2021Mar 31, 2021€67.88M-30.8%
Q4 FY2020Dec 31, 2020€75.84M-32.3%
Q3 FY2020Sep 30, 2020€88.85M+18.8%
Q2 FY2020Jun 30, 2020€87.14M+5.7%
Q1 FY2020Mar 31, 2020€98.06M+4.2%
Q4 FY2019Dec 31, 2019€111.95M+6.0%
Q3 FY2019Sep 30, 2019€74.79M-34.2%
Q2 FY2019Jun 30, 2019€82.46M+150.1%
Q1 FY2019Mar 31, 2019€94.08M+147.6%
Q4 FY2018Dec 31, 2018€105.58M+119.5%
Q3 FY2018Sep 30, 2018€113.72M+168.7%
Q2 FY2018Jun 30, 2018€32.97M-36.7%
Q1 FY2018Mar 31, 2018€38.00M-35.8%
Q4 FY2017Dec 31, 2017€48.10M-49.3%
Q2 FY2017Jun 30, 2017€42.32M-62.5%
Q1 FY2017Mar 31, 2017€52.11M–
Q4 FY2016Dec 31, 2016€59.20M–
Q4 FY2015Dec 31, 2015€94.87M–
Q4 FY2014Dec 31, 2014€112.74M–

More ProQR Therapeutics figures

See a number that looks wrong?